A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase 2
358
about 2.9 years
18–66
13 sites in AL, CA, FL +9
About this study
This trial is testing different drug combinations after a stem cell transplant to prevent graft-versus-host disease (GVHD). It involves comparing new drug combinations to standard treatments, and also assessing the safety of each combination. Participants will receive regular check-ups, take surveys about their well-being, and provide blood and stool samples.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Permitted Concomitant Therapy
- 2.Participate in Prohibited Concomitant Therapy
- 3.Receive Supportive Care: Intravenous immune globulin (IVIG)
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, immunosuppressant (Calcineurin inhibitor; suppresses T-cell activation (reduces IL-2))
injection (Injection), oral (Oral Capsule), oral (Oral Tablet), oral
Primary: Graft-versus-host disease-free, relapse-free survival (GRFS)
Secondary: Graft-versus-host disease-free survival (GFS), Incidence of cytokine release syndrome (CRS), Non-relapse mortality (NRM), Overall survival (OS), Progression-free survival (PFS)
Oncology